Avricore's HealthTab supports inclisiran delivery

Executive Summary

• Avricore Health Inc.'s subsidiary, HealthTab, has been selected to power a new pilot program launched by Barts Health NHS Trust, in collaboration with UCL Partners and the British Heart Foundation (BHF).
• The pilot focuses on delivering inclisiran, a cholesterol-lowering injection, through community pharmacies rather than hospital lipid clinics, marking a significant expansion of HealthTab from primary screening into secondary prevention and therapy-linked workflows.
• The initiative is supported by a £198,000 GBP grant from the BHF and aims to decentralize cardiovascular therapy delivery, reduce hospital burden, and improve access to preventive care for high-risk patients.

Key Details

• Pilot Scope: The program enables community pharmacies to administer inclisiran injections, initiate therapy sooner for patients awaiting specialist care, and provide structured follow-up and monitoring.
• Strategic Expansion: This represents a major shift for HealthTab from primary prevention (screening/testing) to secondary prevention (therapy delivery and management for patients already living with cardiovascular disease).
• Technology Integration: HealthTab integrates with the Ortus-iHealth platform, allowing pharmacy-generated results to flow directly into hospital clinical systems. This complements existing integration with the NHS app (via Patient Knows Best), ensuring data availability for both clinicians and patients.
• Funding: The pilot is supported by a £198,000 GBP grant from the British Heart Foundation.
• Operational Goals: The pilot evaluates the ability of pharmacies to:
  • Administer inclisiran injections traditionally delivered in hospital settings.
  • Identify at-risk patients through HealthTab-powered cholesterol testing.
  • Support long-term lipid management pathways.
• Market Impact: The deployment validates HealthTab as a trusted technology partner in high-profile cardiovascular programs and significantly expands its addressable market within UK community pharmacy networks, aligning with NHS policy to shift chronic condition management into pharmacies.
• Quality Assurance: HealthTab operates a comprehensive quality management program in partnership with CEQAL Inc., ensuring analytical performance and reliability mirroring accredited clinical laboratories.

Notable Quotes

• "Bringing inclisiran injections into community pharmacies is an important milestone for cardiovascular care, and we're proud that HealthTab is helping make it possible," said Rodger Seccombe, chief executive officer of Avricore Health. "We started by empowering pharmacies to identify risk through point-of-care testing. Now, by integrating with the Ortus platform and linking into specialist teams, HealthTab is enabling those same pharmacies to play a meaningful role in secondary prevention and long-term condition management."